In this study, α-galactooligosaccharides (α-GOSs) were synthesized using galactose as the substrate and α-galactosidase from Aspergillus niger as the catalyst. In the reaction, synthesized products of U1, U2, U3, and U4 were detected by high-performance liquid chromatography. By mass spectrometry, nuclear magnetic resonance, and 1-phenyl-3-methyl-5-pyrazolone derivatization, U1 was the mixture of disaccharides of α-d-Gal p-(1→1)-α-d-Gal, α-d-Gal p-(1→2)-α-d-Gal, α-d-Gal p-(1→3)-α-d-Gal, α-d-Gal p-(1→4)-α-d-Gal, U2 was identified to be α-d-Gal p-(1→6)-α-d-Gal, U3 was the mixture of galactotrisaccharides linked by one α-(1→6)-glycosidic linkage and one other α-glycosidic linkage, and U4 was identified as α-d-Gal p-(1→6)-α-d-Gal p-(1→6)-α-d-Gal. Afterward, the synthesized α-GOSs (U1, U2, U3, U4, and their mixture) as well as α-GOSs (manninotriose, stachyose, ciceritol, and verbascose) obtained from natural materials were used as subjects to evaluate their immunomodulatory effects in vitro by culturing mouse macrophage RAW264.7 cells. The results showed that α-GOS with a higher degree of polymerization had better immunomodulatory activity, while to a certain extent, α-GOS linked with α-(1→6)-galactosidic linkage showed a better immunomodulatory effect.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.jafc.8b01939DOI Listing

Publication Analysis

Top Keywords

immunomodulatory effects
8
identified α-d-gal
8
α-d-gal p-1→6-α-d-gal
8
better immunomodulatory
8
α-d-gal
6
immunomodulatory
4
effects enzymatic-synthesized
4
enzymatic-synthesized α-galactooligosaccharides
4
α-galactooligosaccharides evaluation
4
evaluation structure-activity
4

Similar Publications

Melatonin, renowned for regulating sleep-wake cycles, also exhibits notable anti-aging properties for the skin. Synthesized in the pineal gland and various tissues including the skin, melatonin's efficacy arises from its capacity to combat oxidative stress and shield the skin from ultraviolet (UV)-induced damage. Moreover, it curbs melanin production, thereby potentially ameliorating hyperpigmentation.

View Article and Find Full Text PDF

Introduction: Interleukin-10 (IL-10) is a potent immunomodulatory cytokine widely explored as a therapeutic agent for diseases, including myocardial infarction (MI). High-dose IL-10 treatment may not achieve expected outcomes, raising the question of whether IL-10 has dose-dependency, or even uncharted side-effects from overdosing. We hypothesized that IL-10 has dose-dependent effects on macrophage (Mφ) phenotypic transition and cardiac remodeling after MI.

View Article and Find Full Text PDF

Background: Closed head injury (CHI) provokes a prominent neuroinflammation that may lead to long-term health consequences. Microglia plays pivotal and complex roles in neuroinflammation-mediated neuronal insult and repair following CHI. We previously reported that induced neural stem cells (iNSCs) can block the effects of CXCL12/CXCR4 signaling on NF-κB activation in activated microglia by CXCR4 overexpression.

View Article and Find Full Text PDF

Recent advances in oncology research have highlighted the promising synergy between low-dose radiation therapy (LDRT) and immunotherapies, with growing evidence highlighting the unique benefits of the combination. LDRT has emerged as a potent tool for stimulating the immune system, triggering systemic antitumor effects by remodeling the tumor microenvironment. Notably, LDRT demonstrates remarkable efficacy even in challenging metastatic sites such as the liver (uveal) and brain (cutaneous), particularly in advanced melanoma stages.

View Article and Find Full Text PDF

Advancements in bispecific antibodies for multiple myeloma: What's new and what lies ahead.

Semin Hematol

December 2024

Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address:

Recent advancements in multiple myeloma (MM) treatment-including immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, and T cell-redirecting therapies like chimeric antigen receptor (CAR) T cells and bispecific antibodies (BsAbs)-have significantly improved patient outcomes. However, MM remains incurable, highlighting the need for novel therapeutic strategies. BsAbs, which simultaneously target a tumor-specific antigen and CD3 on T cells, have shown promising efficacy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!